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Abstract
Rift Valley fever virus (RVFV) is an important pathogen that affects ruminants and humans. Recently we developed a vaccine
based on nonspreading RVFV (NSR) and showed that a single vaccination with this vaccine protects lambs from viremia and
clinical signs. However, low levels of viral RNA were detected in the blood of vaccinated lambs shortly after challenge
infection. These low levels of virus, when present in a pregnant ewe, could potentially infect the highly susceptible fetus. We
therefore aimed to further improve the efficacy of the NSR vaccine. Here we report the expression of Gn, the major
immunogenic protein of the virus, from the NSR genome. The resulting NSR-Gn vaccine was shown to elicit superior CD8
and CD4-restricted memory responses and improved virus neutralization titers in mice. A dose titration study in lambs
revealed that the highest vaccination dose of 106.3 TCID50/ml protected all lambs from clinical signs and viremia. The lambs
developed neutralizing antibodies within three weeks after vaccination and no anamnestic responses were observed
following challenge. The combined results suggest that sterile immunity was achieved by a single vaccination with the NSR-
Gn vaccine.
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Introduction
Rift Valley fever virus (RVFV) is a mosquito-transmitted
pathogen that infects domesticated ruminants as well as humans.
The virus circulates on the African continent and caused several
outbreaks in countries outside the African mainland [1–5]. In
ruminants, RVFV causes massive abortion storms and high
mortality among young animals [6–8]. In humans the infection
manifests mainly as a acute, self-limiting febrile illness which may
involve headache, malaise, myalgia, arthralgia and gastro-intesti-
nal symptoms. Humans can however develop complications,
which include retinal damage, jaundice, neurological disease and
haemorrhagic fever [9,10]. The case fatality rate in humans is
historically reported to be between 0.5 and 2% [11].
RVFV belongs to the Phlebovirus genus of the family Bunyaviridae.
Typical for a bunyavirus family member, RVFV contains a three-
segmented negative-strand RNA genome, comprising a large (L),
medium (M) and small (S) segment [12]. The L segment encodes
the viral RNA-dependent RNA-polymerase. The S segment
encodes the nucleocapsid (N) protein and a non-structural protein
named NSs. The polymerase and the nucleocapsid protein
together form the replication machinery of the virus. NSs was
identified as the major virulence factor and functions as an
antagonist of host innate immunity [13–17]. The M segment
encodes the two structural glycoproteins Gn and Gc as well as two
accessory proteins [18]. The first is a 14-kDa nonstructural protein
known as NSm, which was shown to have an anti-apoptotic
function [19]. The second is a protein of 78-kD of which the
function is yet unresolved.
RVFV can be transmitted by an impressive variety of mosquito
species, which are globally prevalent. This explains the fear for
future RVF outbreaks in currently unaffected areas, such as
Europe and the USA, where both large populations of susceptible
livestock and vector species are present. The risks of introduction
and subsequent spread of the virus are furthermore increasing by
continued globalization and climate change, respectively [20–24].
Only recently, a new virus of the Bunyaviridae family, the
Schmallenberg virus (SBV, genus Orthobunyavirus), emerged and
spread within a few months accross Europe [25]. SBV was able to
spread so rapidly due to the abundance of competent Culicoı¨des
midges and large numbers of immunologically naı¨ve target
animals. This incursion, as well as that of the bluetongue virus
in Northern Europe in 2006, exemplifies how quickly exotic
arboviruses can adapt to new environments. The high impact of
RVFV on both animal and human health underlines the need for
a safe and effective vaccine that can be used to control RVFV not
only in areas of endemicity, but also in currently unaffected areas.
Several vaccines are available for veterinary use in South Africa
and some other countries on the African continent. A live-
attenuated vaccine, the so-called Smithburn vaccine, elicits solid
immunity but is not safe for pregnant animals [26,27]. An
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inactivated whole-virus vaccine, on the other hand, is safe to use
during all physiological stages, but is expensive to produce and
requires booster administrations for optimal protection [28].
Recently, a third vaccine was registered for use in South Africa,
named Clone 13. This vaccine was shown to be efficacious and
safe in animal studies involving sheep [29] and cattle [30].
However, data on its safety and efficacy in the field have yet to be
reported.
An alternative strategy to develop a live-attenuated vaccine
resulted in the mutagen-attenuated MP-12 strain [31,32].
Although effective in livestock [33–36], concerns remain about
its residual virulence [37,38]. To attenuate the MP-12 vaccine
virus further, derivatives were created that contain deletions in the
NSm-coding region and/or the NSs gene. The MP-12DNSs was
found to be poorly immunogenic, whereas the MP-12DNSm
vaccine showed promise in sheep [38] and cattle [39] immuno-
genicity studies. A similar approach was used to develop a DNSs/
DNSm vaccine virus based on the virulent ZH501 human isolate,
which appears to be safe and protective in pregnant ewes [40].
Alternative vaccine development strategies that focus on
optimal safety have resulted in the development of experimental
subunit vaccines, DNA vaccines and vector vaccines, most of
which await further evaluation in the target species. These
candidate vaccines are described in several comprehensive reviews
[11,41–44].
To create a vaccine that optimally combines the efficacy of live
vaccines with the safety of inactivated vaccines, we and others
previously reported the creation of RVFV replicon particles.
These particles contain two of the three viral genome segments, L
and S, where the NSs gene of the S segment is exchanged for the
gene encoding enhanced green fluorescent protein (eGFP) [45,46].
A single vaccination with the resulting nonspreading RVFV (NSR)
vaccine was shown to induce neutralizing antibodies and to protect
lambs from viremia and clinical signs [47]. However, minor
amounts of viral RNA were detected in the blood of the vaccinated
lambs shortly after challenge infection. We recently found that
RVFV can be transmitted vertically in ewes without detection of
maternal viremia by our most sensitive qRT-PCR [48]. Although
viral RNA was not detected in the blood of these ewes, it was
detected in different organs of both ewes and fetuses. This finding
suggests that sterile immunity is needed to prevent vertical
transmission of the virus. To develop a vaccine that induces
sterile immunity after a single vaccination, we decided to improve
our NSR vaccine by expressing the major immunogenic protein,
Gn, from the NSR small genome segment, resulting in NSR-Gn.
In the current study, we demonstrate that expression of Gn from
the NSR genome improves Gn-specific humoral and cellular
immune responses in mice. A subsequent dose-titration experi-
ment in lambs demonstrated that sterile immunity can be achieved
by a single vaccination with the NSR-Gn vaccine.
Materials and Methods
Ethics statement
All animal experiments were conducted in accordance with the
Dutch Law on Animal Experiments (Wod, ID number
BWBR0003081) and approved by the Animal Ethics Committee
of the Central Veterinary Institute (Permit Numbers: 2012148,
2012108). To minimize suffering of the animals during our
vaccination challenge experiment, lambs were humanely eutha-
nized when they could no longer be stimulated to drink, feed or
stand.
Preparation of the challenge virus
A recombinant RVFV was used as challenge virus. The virus
was produced from cDNA as described previously [45] with
sequences derived from strain 35/74 [49], thereby generating
rec35/74. The titer was determined as 50% tissue culture infective
dose (TCID50) on baby hamster kidney (BHK) cells, using the
Spearman-Ka¨rber algorithm. The virus was handled under
biosafety level-3 laboratory conditions in class-III biosafety
cabinets.
Cells and growth conditions
BHK cells were grown in Glasgow minimal essential medium
(GMEM; Invitrogen, CA, USA), supplemented with 4% tryptose
phosphate broth (Invitrogen), 1% minimum essential medium
nonessential amino acids (MEM NEAA, Invitrogen), 1% Penicil-
lin-Streptomycin (Invitrogen) and 5% fetal bovine serum (FCS;
Bodinco, The Netherlands). BHK-GnGc cells [45] and derivatives
thereof were grown in the above described medium supplemented
with 10% FCS and 1 mg/ml Geneticin (G-418; Promega, USA).
For clarity, complete medium supplemented with either 5 or 10%
FCS is here referred to as GMEM(5) and GMEM(10), respec-
tively. Transfections were performed in Opti-MEMH (Gluta-
MAXTM; Invitrogen), supplemented with 0.2% FCS.
Plasmids
The plasmid encoding the complete L genome segment and the
plasmid encoding the S genome segment in which the NSs gene is
replaced by the eGFP gene (pUC57-L and pUC57-S-eGFP,
respectively) were described previously [45]. In the current work,
the eGFP gene of the pUC57-S-eGFP plasmid was replaced for
the Gn gene, starting at the fourth methionine of the M segment
open reading frame and ending at the sequence ‘‘PIPRHAPIPR’’.
The nucleotide sequence of the Gn gene was codon optimized for
expression in human cells. Plasmid pCAGGS-M encodes the
complete glycoprotein precursor of RVFV under control of the
CMV immediate enhancer/b-actin (CAG) promoter [50].
Flow cytometry
Cells were washed with PBS and permeabilized and fixed with
Cytofix/Cytoperm solution (BD biosciences, NJ, USA). A
monoclonal antibody (mAb) specific for the N protein was used
as primary antibody and FITC-conjugated anti-mouse IgG was
used as the secondary antibody (Santa Cruz Biotechnologies,
USA). Measurements were performed using a CyAn ADP flow
cytometer (Beckman & Coulter, USA) and data analysis was
performed with Kaluza software version 1.2 (Beckman & Coulter).
Immunofluorescence
BHK cells were infected with NSR-Gn at a multiplicity of
infection (MOI) of 0.5 in 24-well plates. Control BHK cells and
Rep-Gn cells were seeded as well. After 48 hours of incubation at
37uC and 5% CO2, cell monolayers were washed with PBS Ca/
Mg and fixed with 4% (w/v) paraformaldehyde for 15 min. The
cells were washed three times with PBS and permeabilized, when
required, with 1% Triton for 5 min. Cells were washed three times
with washing buffer (PBS, 0.05% v/v Tween-20) followed by a
30 min incubation in washing buffer containing 5% FCS. Cells
were incubated with mAb 4-39-cc, which specifically recognizes
Gn [51], for 1 h at 37uC. The cells were subsequently washed
three times with washing buffer and incubated with Texas Red-
conjugated anti-mouse IgG2b (Beckman & Coulter). Cell nuclei
were stained with DAPI staining (Invitrogen), according to the
Improved Nonspreading Rift Valley Fever Vaccine
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manufacturers’ instructions. Images were taken with an AMG
EVOSfl fluorescent microscope.
Preparation of the vaccine
To produce replicon particles containing the S genome segment
encoding either eGFP (S-eGFP) or Gn (S-Gn), cells of the
corresponding replicon cell lines were seeded in T150 cell culture
flasks at a density of 76106 cells/flask in GMEM(10). Medium was
exchanged the next day for 18 ml Opti-MEM and the cells were
transfected with a mixture of 14 mg of the pCAGGS-M plasmid
DNA and 40 ml JetPEI transfection reagent (Polyplus-transfection
SA, France) in 2000 ml saline, following the manufacturers’
instructions. Culture medium was harvested the day after
transfection and cleared from cell debris by centrifugation at
4500 xg for 15 min. When required, replicon particles were
concentrated by ultra-centrifugation at 64 000 xg for 2.5 h and
resuspended in GMEM(5). NSR-Gn replicon particles to be used
for the vaccination of sheep were diluted in Opti-MEM, yielding a
high dose (106.3 TCID50/ml), a medium dose (10
4.6 TCID50/ml)
and a low dose (104.0 TCID50/ml). The indicated NSR-Gn titers
were determined after vaccination.
Vaccination of mice
Six-week-old female BALB/cAnCrl mice (Charles River Lab-
oratories) were housed in two groups of 6 animals and one group
of 4 animals and were kept in type III filter top cages under BSL-3
conditions. Mice were allowed to acclimatize for 6 days, after
which the groups of 6 animals were vaccinated with a titer of
56105 TCID50 of either the NSR vaccine or the NSR-Gn vaccine.
The group of four mice was mock vaccinated with GMEM(5).
Vaccines were administered in a volume of 50 ml by injection into
the thigh muscle using a 25 gauge, 16 mm needle. The mice were
observed daily and no signs of illness were recorded. Blood
samples were obtained on -1, 13, 22 and 29 days post vaccination
(DPV). On DPV 29, the mice were euthanized by cervical
dislocation and spleens were collected.
Enzyme-linked immunospot (ELISPOT) assay
A mouse interferon (IFN)-c antibody pair, consisting of a
capture and a detection antibody (Becton Dickinson, USA) was
used to determine the number of IFN-c secreting spleen cells.
MultiScreenHTS (Millipore, USA) plates were coated overnight
with the capture antibody at 4uC. Unbound antibody was
removed by washing with PBS. The plates were then blocked
with cRPMI (RPMI 1640, Invitrogen, supplemented with 10%
FCS, 1% L-glutamine, 0.1% BME and 1% penicillin/streptomy-
cin) for 30 min at room temperature (RT). Spleens were collected
from mice immediately after euthanization and spleen cells were
isolated as described [52]. Briefly, spleens were gently crushed in a
70 mm cell strainer (BD Bioscience) and cells were collected by
washing the strainer with cRPMI. Erythrocytes were depleted by
incubation of the cells in 5 ml ACK cell lysis buffer (Invitrogen) for
5 minutes. Cells were washed with cRPMI and counted with a
Scepter cell counter (Millipore), supplied with a 40 mm sensor. The
splenocytes were seeded at a density of 56105 cells/well in cRPMI
in triplicate and stimulated overnight at 37uC and 5% CO2 with a
peptide derived from the Gn protein: SYAHHRTLL [53], a
peptide derived from GFP: HYLSTQSAL [54] or a peptide
derived from the nucleoprotein of influenza virus: TYQRTRALV
[55]. Peptides were synthesized by the Genscript Corporation
(USA) and used at a concentration of 5 mg/ml. Additionally, the
ectodomain of the Gn glycoprotein [56] was used for stimulation
at a concentration of 10 mg/ml. Concanavalin A (1 mg/ml) was
used as a positive control and cRPMI as a negative control. After
10 h of stimulation, the cells were removed with chilled water and
the plates were extensively washed with washing buffer (PBS,
0.05% v/v Tween-20). Detection of spots was performed by
incubation of the plates with biotinylated detection antibodies for
2 h at room temperature, followed by 3 washing steps and an
incubation with alkaline phosphatase (ALP)-conjugated streptavi-
din (Mabtech, Sweden) for 1 h at RT. Plates were washed 4 times
with washing buffer and 3 times with PBS to remove residual
Tween-20. Spots were developed with BCIP/NBT chromagen
(Thermo scientific, USA) for 20 min. Plates were dried in a dry
incubator at 37uC. Spots were counted with a CTL ImmunoSpot
apparatus. The number of specific spots was determined as the
average of three repetitions from each sample after the average
number of the respective negative controls was subtracted.
Virus neutralization test with mouse sera
Virus neutralization tests (VNT) with mouse sera were
performed as previously described [45], with some modifications.
Briefly, sera were diluted 1:10 in a 96-well plate and then serially
diluted (2-fold) in a volume of 25 ml in GMEM(5). Another 25 ml
of GMEM(5), containing ,50 NSR particles was added to each
serum dilution and incubated for 1.5 h at 37uC. Next, 30, 000
BHK cells in 50 ml of GMEM(5) were added to each well. After
36–48 hours, the NSR neutralization was determined and titers
were calculated using the Spearman-Ka¨rber method [57,58]. All
samples were tested in triplicate.
Vaccination and challenge of lambs
Texel crossbreed lambs were divided into four groups of eight
animals. At 9–10 weeks of age, lambs were vaccinated via the
intramuscular route (right thigh) with a high-dose (HD,
106.3 TCID50/ml), medium dose (MD, 10
4.6 TCID50/ml) or low
dose (LD, 104.0 TCID50/ml) of the NSR-Gn vaccine in a 1 ml
volume or mock-vaccinated with Opti-MEM. Three weeks after
vaccination, all lambs were challenged via the intravenous route
with 105 TCID50 of RVFV rec35/74. Animals were sedated
before intravenous inoculation (jugular vein) by intramuscular
administration of medetomidine (40 mg/kg medetomidine hydro-
chloride, SedatorH, Eurovet, The Netherlands). For vaccination
and challenge, 18 gauge, 25 mm needles were used. Rectal
temperatures were determined daily from the day of arrival until
the day of euthanasia. Fever was defined as a rectal temperature
above 40.5uC. This threshold was determined as the average plus
three times the standard deviation of the rectal temperatures of all
animals, measured from 27 to 21 DPC. EDTA blood samples
were obtained daily during the first week following challenge and
subsequently on 9, 11, 14 and 21 days post challenge (DPC).
Serum samples were collected on 221, 214, 27, 0, 7, 14 and 21
DPC. The surviving animals were euthanized three weeks after the
challenge by exsanguination, after being anesthetized with 50 mg/
kg sodium pentobarbital (EuthasolH, ASTfarma BV, The Nether-
lands) applied via the intravenous route. Plasma samples were
analysed with quantitative real-time PCR as described previously
[47]. Virus isolation was performed as previously described [47].
Sera were analysed for the presence of anti-N antibodies with a
commercial competition ELISA (ID-VET, France) according to
the manufacturers’ instructions. Virus neutralization titers were
determined by a virus neutralization test (VNT) as described [59].
Statistical analysis.
Data from the ELISPOT assay and the virus neutralization
assay of the mouse experiment were analysed with the Mann-
Whitney non-parametric test, using GraphPad Prism version 5.00
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for Windows (GraphPad Software, USA). Statistical differences
with p-values,0.05 were considered significant.
Results
Creation of a replicon cell line expressing Gn
To produce replicon particles that express the Gn glycoprotein
from the S genome segment, the NSs gene was replaced for a
codon-optimized Gn gene (Fig. 1A). A cell line that constitutively
maintains the resulting S-Gn genome segment together with the L
genome segment was created essentially as described previously
[45]. Briefly, BHK-GnGc cells were infected with fowlpox virus
expressing T7 polymerase and subsequently transfected with the
pUC57 plasmids encoding the L and S-Gn genome segments,
together with plasmid pCAGGS-M, which encodes the glycopro-
tein precursor. Cells were repeatedly passaged and transfected
after every cell passage with pCAGGS-M, until more than 98% of
the cells became positive for N protein expression, as determined
by flow cytometry. The resulting cell line was named Rep-Gn.
The expression and localization of the Gn protein in the Rep-
Gn cells was analyzed by immunofluorescence. Consistent with
previous reports [60,61], in permeabilized cells, Gn was mainly
distributed perinuclearly, corresponding to Golgi localization
(Fig. 1B). In cells with intact cell membranes, Gn was detected
at the cell surface (Fig. 1E). Transfection of the Rep-Gn cells with
the pCAGGS-M glycoprotein expression plasmid resulted in the
production of replicon particles that contain the L and S-Gn
segment. The yield of the NSR-Gn particles was determined at
107 TCID50/ml. These particles were used to infect BHK cells
and the synthesis of the Gn protein was analyzed by immunoflu-
orescence. The de novo synthesized protein showed a similar
distribution as observed in the Rep-Gn cell line (Fig. 1C and F).
Immune responses elicited by NSR and NSR-Gn
vaccination of mice
Groups of six mice were vaccinated once via the intramuscular
route with either NSR or NSR-Gn, and four mice were mock-
vaccinated. Sera were collected the day before vaccination and on
DPV 13, 22 and 29. Virus neutralization tests (VNT) revealed the
presence of neutralizing antibodies in the sera of the NSR-Gn-
vaccinated animals on DPV 13, and the titers increased until DPV
22, after which they remained unchanged until 29 DPV (Fig. 2A).
The VNT titers of the NSR vaccinated group were marginal. No
titers were detected in the mock vaccinated group (data not
shown).
Figure 1. Construction of the S-Gn segment and expression of Gn. (A) Schematic representation of the S segment of RVFV (upper panel) and
the S segment in which the NSs gene is replaced for the codon-optimized Gn gene (lower panel). Distribution of Gn in Rep-Gn cells (B and E) and in
BHK cells infected with NSR-Gn at an MOI of 0.5 (C and F). Panels D and G represent BHK control cells. Upper panels represent permeabilized cells and
lower panels represent nonpermeabilized cells. The cells were stained with an anti-Gn monoclonal antibody and a Texas Red-labeled secondary
antibody. Nuclei were visualized by DAPI staining.
doi:10.1371/journal.pone.0077461.g001
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Spleens were collected on DPV 29 from four mice of each group
and from three control mice. Splenocytes were isolated and
stimulated with peptides representing previously reported CD8-
restricted epitopes of the GFP protein or the RVFV Gn protein.
An unrelated peptide derived from the nucleoprotein of influenza
virus was used as a negative control. Additionally, the ectodomain
of the Gn protein was used for cell stimulation to estimate
predominantly the Gn-specific CD4 response. The GFP peptide
Figure 2. Humoral and cellular immune responses elicited by vaccination of mice with NSR or NSR-Gn. (A) VNT titers in sera collected
from mice vaccinated with NSR or NSR-Gn before vaccination (DPV -1) and 13, 22 and 29 DPV. Bars represent average titers (n = 6) of each group with
standard deviation. The detection limit of the assay is depicted by the interrupted line. (B) Detection of IFN-c-producing splenocytes isolated from
mice vaccinated with NSR or NSR-Gn. Splenocytes were isolated and seeded at a density of 56105 cells/well in triplicate and stimulated for 12 hours
with the indicated peptides or the ectodomain of Gn. Bars represent an average number of IFN-c producing cells (n = 4) per group with standard
deviation. The non-parametric Mann-Whitney test was used for statistical analysis and statistical significance between the groups is depicted by
asterisks (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0077461.g002
Figure 3. Rectal temperatures of vaccinated and mock-vaccinated lambs before and after challenge with RVFV. Fever was defined as a
rectal body temperature above 40.5uC (interrupted line). Body temperatures of mock-vaccinated lambs (C1–C8) and lambs vaccinated with a low
dose (L1–L8), medium dose (M1–M8) or high dose (H1–H7) of NSR-Gn are depicted individually.
doi:10.1371/journal.pone.0077461.g003
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induced a clear response in splenocytes from all four NSR-
vaccinated mice. Analyses with the Gn peptide or the Gn
ectodomain revealed significantly higher numbers of IFN-c
producing cells in NSR-Gn-vaccinated mice than in those
vaccinated with NSR. The control peptide did not induce a
measurable response in splenocytes of any of the mice (Fig. 2B).
None of the stimulating agents induced IFN-c secretion in the
spleen cells of the mock vaccinated mice (data not shown).
Sheep dose-titration study
After establishing that expression of Gn from the small genome
segment of NSR particles contributes to both cellular and humoral
immunity, we proceeded with a sheep study to determine the
minimum protective dose. Groups of 8 lambs were vaccinated
with either 104 TCID50/ml (low dose), 10
4.6 TCID50/ml (medium
dose) or 106.3 TCID50/ml (high dose) of NSR-Gn. One group of 8
lambs was included as a challenge control (mock) group. All lambs
were challenged at 21 DPV. Consistent with our previous
experiments, mock-vaccinated lambs developed fever within 2
days after challenge, which lasted on average for four days. In four
lambs of the mock group the fever was multiphasic (Fig. 3). One
lamb in this group (C3) died 7 days after challenge. Post mortem
examination revealed findings typical for RVF and pneumonia.
Two lambs of the low-dose group and two lambs in the medium-
dose group developed fever. When fever occurred in vaccinated
animals, it was delayed with one day and no secondary peaks were
observed. None of the lambs from the high-dose group developed
fever. One of the lambs in this group died from esophagus
obstruction two days after the vaccination, therefore data from
only seven animals are shown.
All mock-vaccinated lambs developed high viremia, reaching
maximum values between 106 and 109.8 RNA copies/ml plasma
as detected by PCR. Viremia lasted for 4 to 7 days (Fig. 4). In the
low-dose and medium-dose groups, viremia correlated with fever
but was of shorter duration compared to the mock group. No
viremia was detected in lambs vaccinated with the high dose of
NSR-Gn.
The plasma samples with the highest PCR titers from each
animal were subjected to virus isolation. Only samples with PCR
titers above 105.5 RNA copies/ml were used as previous attempts
to isolate virus from samples with lower PCR titers were always
unsuccessful. Virus was successfully isolated from the plasma of all
mock vaccinated animals and from two (L1, L3) and one (M2)
plasma samples of the low-dose and medium-dose vaccination
groups, respectively (data not shown).
Livers and brains of all animals were tested for the presence of
viral RNA with qRT-PCR at the end of the experiment. In the
mock vaccinated group, viral RNA was found in the livers of three
lambs (C3, C4 and C6) and in the brain of one lamb (C8). None of
Figure 4. Detection of viral RNA in plasma by qRT-PCR. Plasma samples were collected daily at the first 7 days post challenge (DPC) and
subsequently on DPC 9, 11, 14 and 21. Viral RNA copy numbers detected in individual animals of the mock-vaccinated group (C1–C8), low-dose group
(L1–L8), medium-dose group (M1–M8) and high-dose group (H1–H7) are depicted.
doi:10.1371/journal.pone.0077461.g004
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the vaccinated animals was found positive for viral RNA in the
liver or brain.
Antibody responses in sheep
Sera collected from all animals on the day of vaccination, on the
day of challenge, and three weeks after challenge were tested for
virus neutralizing activity. Neutralizing antibodies were not
detected in any of the sera collected on the day of vaccination
(data not shown) and no neutralizing antibodies were detected in
the sera of the mock-vaccinated animals collected three weeks after
vaccination. Three animals vaccinated with a low dose of NSR-Gn
and four animals that received a medium dose developed
neutralizing antibodies after vaccination (Fig. 5). Lambs in these
groups generally displayed an increase in the neutralizing antibody
titers after challenge, being more prominent in animals that did
not have neutralizing antibodies before challenge. All animals that
received a high dose of NSR-Gn developed neutralizing antibodies
and antibody levels were highest in this group before the challenge
infection. These neutralizing antibody levels did not increase after
challenge. The animals of the mock group developed the highest
VNT titers upon challenge.
In addition to determining the VNT titers, sera were analyzed
for the presence of antibodies against the N protein using the
commercial ID ScreenH Rift Valley fever Competition ELISA kit
(ID-Vet, Montpellier, France). Seven of the eight sera from the
mock-vaccinated animals were scored positive already on day 7
after challenge and in one animal a delayed increase in the
antibody response was observed (Fig. 6). In the low-dose group,
four animals developed an anti-N response similar to that observed
in challenged mock-vaccinated animals and in four other animals
the antibody response was delayed by 7 days (Fig. 6). By DPC 21,
all sera were found positive for anti-N antibodies. Five sera of the
lambs vaccinated with the medium dose were found positive for
anti-N antibodies, one was doubtful and in two animals no anti-N
antibodies were detected at 21 DPC. In the high-dose group, two
samples were found positive, two were deemed doubtful and three
were found negative for the presence of anti-N antibodies at 21
DPC. Although the serum samples from this group were scored
negative before the challenge, there was a clear increase in the
%S/N values, as compared to the mock group and the low- and
medium-dose groups.
Discussion
Vaccines based on replicons can optimally combine the efficacy
of live vaccines with the safety of inactivated or subunit vaccines.
Vaccination with the recently developed NSR replicon vaccine
was shown to reduce challenge virus viremia in lambs to levels
undetectable by virus isolation. Low levels of viral RNA were,
however, detected in the blood of challenged animals by a highly
sensitive qRT-PCR. We recently found that RVFV can be
transferred to the fetus in gestating ewes even when viremia is not
detectable by qRT-PCR. We therefore aimed to improve our
NSR vaccine so that sterile immunity can be achieved. To this
end, the Gn glycoprotein, which is the major target for
neutralizing antibodies, was introduced in the NSR genome.
Figure 5. Virus neutralization test (VNT). Sera were obtained from lambs of the mock group, low-dose group, medium-dose group and high-
dose group. The white bars represent VNT titers determined 21 days post vaccination (DPV) and the black bars represent the VNT titers determined
21 days post challenge (DPC). Results obtained from analysis of each individual animal from the mock-group (C1–C8), low-dose group (L1–L8),
medium-dose group (M1–M8) and high-dose group (H1–H7) are depicted. The detection limit of the assay is represented by an interrupted line.
Lamb C3 died 7 days after challenge, therefore no serum sample was collected at 21 DPC.
doi:10.1371/journal.pone.0077461.g005
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Memory T-cell responses were analyzed using spleen cells of
mice that were vaccinated with NSR expressing eGFP (NSR) or
NSR expressing Gn (NSR-Gn). Stimulation of splenocytes with a
GFP-derived peptide resulted in IFN-c production by spleen cells
of the NSR-vaccinated group. As the eGFP protein is not present
in the NSR particle, we conclude that the observed response
results from eGFP production in vivo. Importantly, a Gn-derived
peptide stimulated significantly higher numbers of IFN-c produc-
ing splenocytes in cultures obtained from NSR-Gn-vaccinated
mice, compared to cultures derived from NSR-vaccinated mice.
Although the Gn protein is incorporated in the NSR particle,
expression of the Gn gene from the NSR genome resulted in a
superior and sustained memory CD8 response. Soluble ectodo-
main of Gn (Gne) was also used for splenocyte stimulation. Soluble
proteins are internalized by antigen presenting cells by endocytosis
and are presented mainly by MHC-II [62,63]. The observed
stimulation by Gne therefore likely represents a CD4+ T-cell
response. Once again, splenocytes collected from NSR-Gn-
vaccinated animals displayed the strongest response, indicating
that the in vivo expression of Gn contributes substantially to the
immunogenicity of the NSR-Gn vaccine. In addition, the VNT
titers of NSR-Gn-vaccinated animals were readily detectable by 13
DPV, while the titers of the NSR group were marginal. This result
demonstrates that expression of Gn by NSR-Gn not only
promotes priming of IFN-c secreting T-cells, but also stimulates
neutralizing antibody responses. The combined results of this
experiment underscore the added value of Gn expression from the
NSR genome.
We previously demonstrated that a single vaccination with 107
TCID50 of NSR protects lambs from viremia and clinical signs,
although protection was not sterile [47]. Since we anticipated
superior efficacy of the NSR-Gn vaccine, we continued with
determining the minimal protective dose of this vaccine in lambs.
Vaccination with a low dose (104.0 TCID50/ml) prevented
detectable viremia in five lambs and strongly reduced viremia in
the remaining three animals. No viremia was detected in 6 of 8
lambs that were vaccinated with a medium dose (104.6 TCID50/
ml), whereas two lambs did develop low-level viremia. It is
important to note, however, that neutralizing antibodies were
boosted after challenge in these two groups. A sharp increase in
the anti-N response was noted in the low-dose group after
challenge, similar to that observed in the mock group. The group
of lambs vaccinated with a medium dose displayed a more variable
pattern, with two animals not developing anti-N antibodies and
two others showing only a minor increase in the anti-N responses
after challenge. The observed boosts of anti-N antibodies as well as
neutralizing antibodies after challenge suggests that virus replica-
tion occurred at a low level in the lambs of these two groups. Some
lambs of the low-dose and medium-dose groups did not develop
detectable levels of neutralizing antibodies after vaccination, but
were nevertheless solidly protected from challenge infection. The
observed protection in these animals is therefore attributed to T-
Figure 6. Detection of anti-N antibodies by ELISA. Sera were obtained 7, 14 and 21 days post vaccination (DPV) and at 0, 7, 14 and 21 days post
challenge (DPC). Titers are expressed as percentage competition ratio of the optical densities (OD) of the sample and the OD of the negative control
(%S/N). All values lower than 40% are considered positive, between 40–50% are considered doubtful and above 50% are considered negative. The
40% and 50% cut-offs are represented by solid and interrupted lines, respectively. Results obtained from analysis of each individual animal from the
mock-group (C1–C8), low-dose group (L1–L8), medium-dose group (M1–M8) or high-dose group (H1–H7) are depicted.
doi:10.1371/journal.pone.0077461.g006
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cell responses. No viral RNA was detected upon challenge in any
of the lambs vaccinated with the high dose (106.3 TCID50/ml) of
NSR-Gn. This result correlates with the absence of an anamnestic
antibody response after challenge. Taken together, these data
suggest that challenge virus was not able to replicate in these lambs
and that sterile immunity was achieved.
Although a clear dose-response was demonstrated in this study,
it is interesting to note that even vaccination with a low dose of
NSR-Gn can provide sterile immunity in lambs. After inoculation
of NSR-Gn in the muscle, the nonspreading virus can infect not
only muscle cells, but also macrophages and dendritic cells. RVFV
was recently shown to use dendritic cell (DC)-specific intercellular
adhesion molecule 3-grabbing nonintegrin (DC-SIGN) as a
receptor, which is present on both dendritic cells and macrophages
[64]. DCs and macrophages are possibly used by RVFV as ‘‘trojan
horses’’ to migrate to secondary sites of replication, such as the
lymph nodes. While doing so, the virus must prevent the activation
of these immune cells, in which the NSs protein is likely to play a
role. Since NSs is lacking from NSR-Gn particles, these particles
are probably unable to prevent activation of the macrophages and
DCs, thereby facilitating a potent priming of the immune
response. We propose that vaccination with a low dose of NSR-
Gn can provide sterile immunity if a sufficient number of
macrophages and dendritic cells are infected by NSR-Gn. If this
hypothesis proves to be correct, it will be interesting to target
dermal dendritic cells by intradermal vaccination with the goal to
lower the protective dose of the NSR-Gn vaccine.
In conclusion, here we demonstrate that expression of the Gn
protein from the NSR genome results in improved cellular and
humoral immune responses and that the resulting NSR-Gn
vaccine provides sterile immunity in lambs after a single
vaccination. Given its high efficacy and safety profile, it would
be valuable to evaluate the use of the NSR-Gn vaccine as a human
vaccine as well.
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